Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982993 | 1.00 | KCNA5 (0.38) | KCNA5BRD4IRAK4PDK2 | |
| SCHEMBL981131 | 1.00 | KCNA5 (0.38) | KCNA5BRD4IRAK4PDK2 | |
| SCHEMBL16030453 | 0.90 | IRAK4 (0.36) | KCNA5BRD4IRAK4 | |
| Tert-Butyl Formate SCHEMBL27984964 | 0.86 | IRAK4 (0.35) | KCNA5BRD4IRAK4PDK2 | |
| Tert-Butyl Formate SCHEMBL27984962 | 0.86 | IRAK4 (0.35) | KCNA5BRD4IRAK4PDK2 | |
| SCHEMBL28460243 | 0.82 | CA2 (0.38) | KCNA5IRAK4PDK2 | |
| SCHEMBL10666154 | 0.79 | ITGB1 (0.39) | BRD4 | |
| SCHEMBL11062632 | 0.79 | ITGB1 (0.39) | BRD4 | |
| SCHEMBL14285551 | 0.77 | — | — | |
| SCHEMBL12409742 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| EP-4402139-A1 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | Bisichem Co., Ltd. (KR) | 2024-07-24 | — | — | EP | disclosed |
| US-20240083892-A1 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2024-03-14 | — | — | US | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-07-06 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4159739-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023043284-A1 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022208269-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-10-06 | — | — | WO | disclosed |
| US-20110015200-A1 | NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS | NEUROTUNE AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7119207-B2 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| US-6509359-B1 | Use as a neuramninidase inhibitor in virus | BIOCRYST PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-1999014191-A1 | PYRROLIDIN-2-ONE COMPOUNDS AND THEIR USE AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1999-03-25 | — | — | WO | disclosed |
| US-4621145-A | Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-11-04 | — | — | US | disclosed |
| EP-0116257-B1 | PROCESS FOR PREPARING 4-AMINO-5-HEXENOIC ACID | MERRELL DOW FRANCE ET CIE (FR) | 1986-08-27 | — | — | EP | disclosed |
| EP-0116257-A1 | Process for preparing 4-amino-5-hexenoic acid | MERRELL DOW FRANCE ET CIE (FR) | 1984-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083892-A1 | FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS | RIPK1, RIPK3, RIPK4 | KCNA5 4371/4885BRD4 1264/4885IRAK4 97/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | KCNA5 2378/4885BRD4 2416/4885IRAK4 3397/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | KCNA5 4134/4885BRD4 1279/4885IRAK4 2781/4885 |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | ACE2, ACE, TMPRSS2 | KCNA5 4658/4885BRD4 460/4885IRAK4 1311/4885 |
| US-20110015200-A1 | NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS | OPRL1, CNR1, OPRK1 | KCNA5 335/4885BRD4 2532/4885IRAK4 3272/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | KCNA5 4591/4885BRD4 268/4885IRAK4 1959/4885 |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | KCNA5 56/4885BRD4 828/4885IRAK4 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.